


Injection treatment

for more radiant and rejuvenated skin



Anatomical areas:

- Face (incl. tear trough deformities)
- Neck
- Hands

Purpose:

- As a standalone therapy, combined formulation determines a synergic action to significantly improve skin hydration in association with fostering fibroblasts resulting in the restauration or/and improvement of the skin elasticity, trophism, firmness, tone and appearance.
- Remodelling of striae distensae and depressed scars, as part of personalised treatment protocols.¹
- Skin Enhancement Technique (SET) to generates a synergistic effect and helps prepare the skin before other aesthetic procedures: laser, radio frequency, filler, peeling, needling and surgery.²

 Priming the dermal fibroblasts to full PN-HPT® activation over the following treatment sessions.⁴

Depth:

Intradermal¹

Treatment protocols and injection techniques

- 2 ml per session
- One session every 14 or 21 days for a total of 3 sessions for normal skin and 4 session for advanced aging skin
- Needle microdroplet or linear retrograde



Concentration: PN-HPT® 20 mg/2 ml non-crosslinked hyaluronic acid 20 mg/2 ml mannitol to slow down hyaluronic acid degradation³
Pack: 1×2 ml pre-filled syringe
Needle: 2×30 G ½, 13 mm
Depth of injection: intradermal



Exploring the potential of PhilArt Next in facial middle third rejuvenation.⁴

An open-design, exploratory prospective cohort study in 40 real-life ambulatorily treated women has been performed to probe the value of PhilArt Next in middle third rejuvenation.

Treatment protocol:

- At baseline treatment with intradermal injections of 2 ml PhilArt Next, containing 10 mg/ml Polynucleotides and 10 mg/ml non-crossed link hyaluronic acid, and 200 mM mannitol.
- After 3 weeks treatment with intradermal injection of 2ml of PhilArt Next 20 mg/ml
- After 6 weeks treatment with intradermal injections of 2 ml PhilArt Next, containing 10 mg/ml Polynucleotides and 10 mg/ml non-crossed link hyaluronic acid, and 200 mM mannitol.

Efficacy:

- Significant improvement of overall skin quality and texture (from 7.0 ± 1.06 at baseline session to 7.8 ± 0.99 at follow-up)
- Significant improvements of wrinkles and skin roughness, elasticity, and brightness (-17.1%, +39.6%, and +51.1%, respectively)
- The individual satisfaction score was 8.0 ± 0.87 out of a theoretical maximum of 10

Safety:

- All side effects were no more severe than mild and transient discomfort, irritation or pain at the injection site.
- No systemic adverse events have been reported

¹ PhilArt next IFU | 2. Cavallini M, Bartoletti E, Maioli L, Massirone A, Pia Palmieri I, Papagni M et al. Consensus report on the use of PN-HPT™ (polynucleotides highly purified technology) in aesthetic medicine. J Cosmet Dermatol. 2021 Mar;20(3):922-928. doi: 10.1111/jocd.13679. Epub 2020 Sep 21. PMID: 32799391; PMCID: PMC7984045 | 3. Mendoza G, Alvarez Al, Pulido MM, Molina AJ, Merino G, Real R et al. Inhibitory effects of different antioxidants on hyaluronan depolymerization. Carbohydr Res. 2007 Jan 15;342(1):96-102. doi: 10.1016/j.carres.2006.10.027. Epub 2006 Nov 2. PMID: 17123492. | 4. Cavallini M, De Luca C, Prussia G, Raichi M. PN-HPT® (Polynucleotides Highly Purified Technology) in facial middle third rejuvenation. Exploring the potential. J Cosmet Dermatol. 2022 Feb;21(2):615-624. doi: 10.1111/jocd.14578. Epub 2021 Nov 17. PMID: 34791770; PMCID: PMC9299481.